Answers are grounded in this paper and cite their sources.
Living biohybrid materials offer a unique opportunity to couple oral drug delivery with host-microbiome interactions, yet maintaining carrier integrity, cargo retention, and biological function under gastrointestinal constraints remains challenging. Here, we engineered a hyaluronic acid (HA)-coated Akkermansia muciniphila-paeoniflorin biohybrid (PF@AKK@HA) through vacuum-enabled paeoniflorin loading followed by HA shell stabilization. Structural and colloidal analyses confirmed preserved bacterial morphology, stable negative surface charge, and HA-associated surface coating, while simulated gastrointestinal assays supported enhanced carrier resilience and diffusion-limited paeoniflorin release. In a zebrafish model of chronic chemical-induced reproductive dysfunction triggered by 6PPD-quinone, oral PF@AKK@HA administration substantially improved fecundity, gonadosomatic index, gonadal histology, endocrine balance, oxidative-stress readouts, and F1 developmental outcomes. Integrated gonadal transcriptomics and gut microbiota profiling further associated these protective effects with partial recovery of host-microbiome metabolic programs, particularly PPAR signaling, retinoid metabolism, and bile acid-related pathways. This work establishes PF@AKK@HA as a living oral biohybrid material that links sustained phytochemical delivery with microbiome-targeted gut-gonad axis protection.
No takes yet. Share an insight, caveat, or question.
Yi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: